Elmind Capital LP Takes $26.72 Million Position in Viridian Therapeutics, Inc. $VRDN

Elmind Capital LP acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 858,631 shares of the company’s stock, valued at approximately $26,721,000. Viridian Therapeutics comprises approximately 7.9% of Elmind Capital LP’s investment portfolio, making the stock its 3rd biggest position. Elmind Capital LP owned approximately 0.90% of Viridian Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new position in shares of Viridian Therapeutics during the 3rd quarter valued at about $35,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $36,000. Larson Financial Group LLC bought a new position in shares of Viridian Therapeutics during the 3rd quarter valued at about $52,000. US Bancorp DE increased its position in shares of Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the last quarter. Finally, Clearstead Advisors LLC increased its position in shares of Viridian Therapeutics by 3,868.3% during the 3rd quarter. Clearstead Advisors LLC now owns 5,000 shares of the company’s stock valued at $108,000 after purchasing an additional 4,874 shares during the last quarter.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director directly owned 5,090,928 shares in the company, valued at $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is currently owned by insiders.

Viridian Therapeutics Price Performance

VRDN opened at $16.71 on Thursday. The stock’s 50 day simple moving average is $15.91 and its 200 day simple moving average is $24.92. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. Viridian Therapeutics, Inc. has a 1 year low of $13.18 and a 1 year high of $34.29. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -5.03 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same period last year, the company earned ($0.87) EPS. Viridian Therapeutics’s revenue for the quarter was up 95.8% compared to the same quarter last year. As a group, analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on VRDN shares. Wells Fargo & Company reduced their price objective on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Royal Bank Of Canada increased their price objective on Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Stifel Nicolaus set a $39.00 price target on Viridian Therapeutics in a research report on Wednesday, May 13th. Finally, Wedbush reduced their price target on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.14.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.